SCHEMBL7701598

SCHEMBL7701598

N[C@H]1C[C@@H]1c1ccc(-c2cc(O)ccc2Cl)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 20/20 1.00
MAOB P27338 3/20 0.57
MAOA P21397 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL526738 1.00 KDM1A (1.00) KDM1AMAOBMAOA
SCHEMBL526737 1.00 KDM1A (1.00) KDM1AMAOBMAOA
Hydrochloric Acid SCHEMBL528304 0.99 KDM1A (0.97) KDM1AMAOBMAOA
Hydrochloric Acid SCHEMBL528303 0.99 KDM1A (0.97) KDM1AMAOBMAOA
SCHEMBL526952 0.84 KDM1A (1.00) KDM1AMAOBMAOA
SCHEMBL15136607 0.84 KDM1A (1.00) KDM1AMAOBMAOA
SCHEMBL526953 0.84 KDM1A (1.00) KDM1AMAOBMAOA
Hydrochloric Acid SCHEMBL527786 0.83 KDM1A (0.97) KDM1AMAOBMAOA
Hydrochloric Acid SCHEMBL527787 0.83 KDM1A (0.97) KDM1AMAOBMAOA
SCHEMBL20923929 0.82 KDM1A (0.69) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2598480-B1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2019-04-24 EP disclosed
US-9676701-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2017-06-13 US disclosed
US-9676701-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2017-06-13 US disclosed
US-9676701-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2017-06-13 US disclosed
US-20160052865-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. 2016-02-25 US disclosed
US-9006449-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2015-04-14 US disclosed
US-9006449-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2015-04-14 US disclosed
US-9006449-B2 Cyclopropylamine derivatives useful as LSD1 inhibitors ORYZON GENOMICS, S.A. (ES) 2015-04-14 US disclosed
US-20130197013-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. (ES) 2013-08-01 US disclosed
US-20130197013-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. (ES) 2013-08-01 US disclosed
US-20130197013-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. (ES) 2013-08-01 US disclosed
WO-2012013727-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. (ES) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052865-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3A KDM1A 2/4885MAOB 173/4885MAOA 141/4885
US-20130197013-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3A KDM1A 2/4885MAOB 173/4885MAOA 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.